- Home
- BGMS vs ALBT Comparison
BGMS vs ALBT Comparison
Compare BGMS & ALBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BGMS | ALBT |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | Malaysia | United States |
| Employees | N/A | 5 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0M | 4.1M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | BGMS | ALBT |
|---|---|---|
| Price | $0.91 | $0.69 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 17.3K | ★ 8.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,333,403.00 |
| Revenue This Year | $137.21 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 6.19 |
| 52 Week Low | $0.74 | $0.42 |
| 52 Week High | $6.70 | $7.89 |
Technical Indicators
Market Signals| Indicator | BGMS | ALBT |
|---|---|---|
| Relative Strength Index (RSI) | 36.87 | 43.75 |
| Support Level | $0.74 | $0.47 |
| Resistance Level | $1.12 | $1.44 |
| Average True Range (ATR) | 0.07 | 0.20 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 54.96 | 17.60 |
Price Performance
Historical ComparisonAbout BGMS Bio Green Med Solution Inc.
Bio Green Med Solution Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.
About ALBT Avalon GloboCare Corp.
Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. The company has two reportable segments: the real property operating segment, which is the key revenue driver, and the laboratory testing services segment. The company focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.